VaxGen's AIDSVAX vaccine, based on a recombinant gp120 coat protein, failed to prevent HIV infection or even slow the development of disease in its second phase III clinical trial, conducted in Thailand and reported this month.The results were even worse than those from the first trial in the United States and elsewhere, reported in February. Nevertheless, many important lessons for future HIV vaccines can be learned from the two studies, said José Esparza, coordinator of the World Health O

UK farm scale evaluations give half-cheer for genetically modified maize

over GM crops story

Public needs more truly objective science communication, says new MRC chief

WHO expert says a global biosecurity system needed to keep labs in shape

It's time to take risks in order to save lives, UN agency says

, second paper also retracted

Additional published research affected by drug mix-up

should publish referees' reports

New SARS case worked in containment lab that did work on SARS virus

South Africa's Medicines Control Council petitioned to allow continued use of AIDS prevention drug

South Africa's AIDS conference to debate Medicines Control Council rejection of AIDS prevention drug